BioVerse episode 08：Recap of AACR2024 | 药时代直播间

2024-04-07

AACR会议疫苗细胞疗法

立即预约直播汇聚群英智慧，闪亮你我星光Together, Spark Biomedicine!Join Bioverse webinar episode 8 to review the exciting presentations from AACR 2024 in San Diego. Our experts of cancer research and drug development will discuss:The industry-shaping data of ADC and radiopharmaceuticalClinical data from cell therapy, bispecific antibody, cancer vaccine, targeted therapy, and other drug classesNovel targets and industry-shaping scientific breakthroughsPractice-changing or market-moving clinical trial dataHighlights of presentations from Asian biotech companiesEvent details主题：BioVerse episode 08 - Recap of AACR2024时间: 2024年4月11日 Thur 9:00 AM（EST）/ 2024年4月11日周四 9:00 PM（北京时间）地点: 药时代视频号Speakers introLihua Yu, PhDAs LifeMine’s Chief Data Officer, Lihua brings vast experience in drug discovery from target identification to translational medicine, data science, and early clinical development. Lihua is passionate about integrating and applying data science across R&D, partnering with all functions to drive the platform and pipeline forward.Lihua comes from Fog Pharma where she was leading the Data Science function and co-leading the discovery platform and new targets. Prior to Fog, Lihua was at H3 where she first served at head of bioinformatics, later as Chief Data Science officer and President. Preceding H3, Lihua was the cancer bioinformatics leader at AstraZeneca Oncology US.Lihua holds a Ph.D. in biomedical engineering from Boston University, studying under Dr. Temple Smith, and M.E. and B.E. in biomedical engineering from Tsinghua University in Beijing, China.Cassian Yee, MDDr. Yee is a Professor in the Division of Cancer Medicine, Director of the Program in TCR-based Therapeutics and Co-Director of the Adoptive Cellular Therapy Platform at UT MD Anderson Cancer Center. He is an elected member of the American Society of Clinical Investigator, former co-Leader of the Stand Up to Cancer- AACR/CRI Dream Team and recipient of Damon Runyon Cancer Research Foundation Physician Scientist award, and the Rao Potul Basic Science Award. He holds an endowed position as the Kenneth Muller Professorship of Melanoma Research. Over the last 20+ years, Dr. Yee has pioneered a form of ACT, known as Endogenous T Cell (ETC) therapy, using peripheral blood to generate a uniform population of antigen-specific memory T cells. He has conceived and executed several IND-approved first-in-human clinical studies establishing principles of T cell persistence, memory and antigen-spreading He is corresponding or lead author in > 80 publications, including The New England Journal of Medicine, Nature, Science, Science Immunology, Science Translational Medicine, Nature Medicine, Journal of Clinical Oncology, Journal of Experimental Medicine, Gastroenterology and Cancer Immunology Research. He holds > 15 worldwide patents on ex vivo generation of antigen specific T cells, memory reprogramming, and antigen discovery and seeks to extend immunotherapy-based cancer treatments globally. He is scientific co-founder of Immatics US and is the founder of Mongoose Bio, an early stage cell therapy company poised to treat patients with gastric, esophageal, lung , breast bladder, ovarian, uterine and other cancers. Jeff Bockman, PhDJeff leads the Oncology and Virology Practices at Lumanity. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at Cello Health BioConsulting, now Lumanity. He often speaks at conferences on scientific and commercial issues in cancer, especially immuno-oncology.Before joining Cello Health BioConsulting, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients – Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions – and holds four patents in the use of ribozymes.He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.Jeff is a member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Society of Gene and Cell Therapy (ASGCT), the Society for Immunotherapy of Cancer (SITC) and the New York Academy of Sciences (NYAS).Jeff is a mentor for the NCI Innovation Conference, a judge for the Citeline Awards, an advisor to the JPM Biotech Showcase, a member of the Advisory "Group" to Skipper Bio Med (a preclinical research consultancy that provides pro bono services to academic and industry groups, developing promising lung and/or pancreatic cancer therapeutics/device. Skipper is fully supported by a private US family that has been personally impacted by these cancers and is committed to bridging the research “valley of death”).Jeff is also part of the Clinical Advisory Board of ImmunOS (an immunotherapy company based in Zurich) and the Scientific Advisory Board of hC Bioscience (a novel RNA-based platform company in Cambridge, MA).Leon ‘Jun’ Tang, PhD (BioVerse webinar host)Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center. OrganizerPartner &Collaborators封面图来源：123rf131亿美元！强生收购又一家心血管器械巨头，3年300亿美元收购，打算重当器械一哥？中美关系能否扑灭ADC投资热潮？一个靶点触发一家Biotech的重生！点击在看，共济新药研发浪潮